Additionally, Leung et al. (150) established sorafenib-resistant HCC cell lines and sorafenib-resistant PDX mouse models to evaluate the combined therapeutic effect of sorafenib and Src homology 2 domain-containing phosphatase 2 (SHP2) inhibitor on sorafenib-resistant HCC. This evidence concerns the gene PTPN11 and hepatocellular carcinoma.